SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as users compare it to other high-growth cryptos like $HYPE.X, with some anticipating significant gains and highlighting its strong backing. The community is actively discussing its potential to reach new price levels, fueled by its recent listing and perceived undervaluation, while also comparing it to similar projects.

Aventus

Aventus ($AVT.X) is trending as community members highlight its low market cap and potential for significant gains, with some pointing to a possible partnership with the Truth Network as a catalyst. Many are discussing the bullish chart patterns and rising volume, speculating about a potential breakout. Aventus's integration with Polkadot and real-world partnerships are also being mentioned as reasons for optimism.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending, with community chatter focused on labeling traders as "suckers" and anticipating both bullish and bearish price movements. Discussions also highlight recent developments within the Tezos ecosystem, including the launch of Sugar Match on Etherlink and tokenized uranium (xU3O8) becoming available on the platform. Some users are pointing to signals of a potential breakout while others anticipate a price decline.

DePhyneAI is a decentralized physical AI infrastructure enabling autonomous devices such as drones, robots, and edge sensors to perform intelligent tasks while earning rewards in the native token, $DPHY. The network is permissionless, community-owned, and designed to bring scalable, secure AI computation to the edge of the real world.  1. Introduction Artificial Intelligence has historically been confined to centralized cloud platforms. However, as physical devices grow more capable, the future lies in enabling intelligence directly on the edge - embedded in the real world. DePhyneAI empowers a decentralized network of autonomous agents to train, infer, and collaborate - creating a self-sustaining AI ecosystem governed by a native token economy.  What is DePhyneAI? DePhyneAI is an open, decentralized network where physical devices act as nodes. Each device contributes compute, data, or services and is rewarded in $DPHY tokens. The network supports:  Federated learning and on-device AI inference Secure blockchain-based coordination Real-time decision-making in physical environments Use Cases DePhyneAI supports diverse real-world applications:  Logistics: AI-enabled autonomous drone deliveries Agriculture: Monitoring soil, crop health, irrigation using robotic systems Smart Cities: Surveillance, traffic analysis, energy optimization Disaster Response: Real-time aerial monitoring and situational AI Why $DPHY Matters The $DPHY token is the lifeblood of the DePhyneAI network. It serves multiple purposes:  Rewards: Earned by node operators who run AI tasks Access: Used to access AI models, data feeds, and services Governance: Voting and proposal mechanisms Staking: Ensures quality and uptime guarantees

DePhyneAI

DePhyneAI ($DPHYAI.X) is trending as part of the AI-driven crypto narrative, with community members actively discussing its potential within the Solana ecosystem. Many are drawn to its early-stage nature and are evaluating its utility and performance within platforms like Phantom. The broader context is the increasing interest in AI-related crypto projects.

Tether (USDT) is a cryptocurrency with a value meant to mirror the value of the U.S. dollar. The idea was to create a stable cryptocurrency that can be used like digital dollars. Coins that serve this purpose of being a stable dollar substitute are called “stable coins.” Tether is the most popular stable coin and even acts as a dollar replacement on many popular exchanges! According to their site, Tether converts cash into digital currency, to anchor or “tether” the value of the coin to the price of national currencies like the US dollar, the Euro, and the Yen. Like other cryptos it uses blockchain. Unlike other cryptos, it is [according to the official Tether site] “100% backed by USD” (USD is held in reserve). The primary use of Tether is that it offers some stability to the otherwise volatile crypto space and offers liquidity to exchanges who can’t deal in dollars and with banks (for example to the sometimes controversial but leading exchange Bitfinex).  The digital coins are issued by a company called Tether Limited that is governed by the laws of the British Virgin Islands, according to the legal part of its website. It is incorporated in Hong Kong. It has emerged that Jan Ludovicus van der Velde is the CEO of cryptocurrency exchange Bitfinex, which has been accused of being involved in the price manipulation of bitcoin, as well as tether. Many people trading on exchanges, including Bitfinex, will use tether to buy other cryptocurrencies like bitcoin. Tether Limited argues that using this method to buy virtual currencies allows users to move fiat in and out of an exchange more quickly and cheaply. Also, exchanges typically have rocky relationships with banks, and using Tether is a way to circumvent that.  USDT is fairly simple to use. Once on exchanges like Poloniex or Bittrex, it can be used to purchase Bitcoin and other cryptocurrencies. It can be easily transferred from an exchange to any Omni Layer enabled wallet. Tether has no transaction fees, although external wallets and exchanges may charge one. In order to convert USDT to USD and vise versa through the Tether.to Platform, users must pay a small fee. Buying and selling Tether for Bitcoin can be done through a variety of exchanges like the ones mentioned previously or through the Tether.to platform, which also allows the conversion between USD to and from your bank account.

Tether

Tether is trending due to discussions around its market dominance and potential regulatory impacts, particularly the GENIUS Act. The community is also focused on Tether's partnerships, such as with Rumble, and its increasing presence in traditional finance, including holdings of US Treasuries. Debates persist regarding Tether's transparency and the implications of its expansion into new sectors.

Useless Paper

The community is actively discussing potential breakouts and bullish signals for DEGREE.X, with many noting its connection to $AVT.X and suggesting it as a promising 'moon bag' addition alongside other projects like $BROKE.X.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending as investors discuss its potential role in the "Golden Dome" missile defense system, drawing comparisons to other high-growth stocks. Community chatter also highlights the company's increasing presence in the defense sector and rising A&D revenues. Some analysts have recently updated their rating for nLight to Overweight.

Terner is an AI-powered platform on Solana that enables users to create, deploy, and crowdfund innovative projects through natural language interaction. The platform combines advanced AI capabilities with blockchain technology to democratize project creation, offering tools for building web applications, bots, and various digital solutions while providing automated deployment and investment opportunities for creators and investors alike.

Terner

Terner.X is trending as users discuss its potential as an AI-powered project on the Solana blockchain, with many highlighting its availability on Phantom Wallet. The community is optimistic about its future, referencing a target of a 10M market cap and a potential for substantial growth. Some users are comparing it to other tokens, while others are focused on accumulating it.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE.X is trending as community members compare it to other DEXs and speculate on its potential for growth, particularly as it hits new all-time highs.  Discussions also focus on how to gain exposure to HYPE.X, given its limited availability on major U.S. exchanges, with some pointing to companies holding HYPE as part of their treasury strategy. The community is closely watching developments around stablecoin integrations and trading fee updates on the Hyperliquid platform.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

The crypto, 401JK.X, is trending as users discuss its potential as an alternative retirement plan, contrasting it with traditional 401(k)s. The community is actively sharing bullish sentiment and eyeing new all-time highs, emphasizing long-term holding and dismissing paper hands. This memecoin on the Solana network is attracting attention with its narrative of early retirement and community-driven growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Options Traders Betting on a Big Move in BCRX Stock?

Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.

BioCryst Pharmaceuticals, Inc. (BCRX) is now looking forward to data on its Netherton Syndrome and DME pipeline programs after its second-quarter earnings beat Wall Street expectations on the strong performance of its Orladeyo drug.“Our Netherton Syndrome and DME (diabetic macular edema) pipeline programs remain on track to have some data by the end of the year,” said CEO Jon Stonehouse on the company’s earnings call on Monday. The company is enrolling patients for an early-stage trial of both investigational drugs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> is trending in the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_11_07_20_AM_png_98d2936188.webp" alt="BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>BCRX's Sentiment Meter and Message Volume as of 11:05 a.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock’s fair valuation is double its current level.<stembedurl>https://stocktwits.com/doublebtx/message/623619202</stembedurl>Another expressed disappointment at the stock’s slow rally.<stembedurl>https://stocktwits.com/coleslaugh/message/623622668</stembedurl>Netherton syndrome is a rare genetic disorder primarily affecting the skin, hair, and immune system, in which patients experience severe skin problems, including redness, scaling, and blistering, as well as hair abnormalities like bamboo hair.DME, meanwhile, is a leading cause of vision loss in people with diabetes. Fluid accumulates in the central part of the eye’s retina, causing swelling and blurry or distorted vision.A company spokesperson said on the call that the firm is looking at data on several endpoints, including the penetration of the drug in the skin, and on potential efficacy endpoints, including itching and healing of the skin with its investigational drug for Netherton syndrome. For the company’s investigational drug for DME, the company is looking at the effect of the drug on the retina and the potential for reducing the swelling in the retina after a dose of the drug.For the second quarter, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-reports-second-quarter-2025-financial-results-and">reported</a> total revenue of $163.35 million, compared to $109.33 million in the corresponding quarter of 2024, and above an analyst estimate of $149.22&nbsp;&nbsp;&nbsp;&nbsp;million, as per data from Fiscal AI.Orladeyo, the company’s medicine used to prevent attacks of hereditary angioedema (HAE), accounted for a whopping 96% of the company’s total revenue in the quarter. Orladeyo's net revenue in the quarter jumped 45% to $156.8 million.For the full year, the company now expects global net Orladeyo revenue to be between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business. Biocryst in June said that it has entered into a definitive agreement to sell its European Orladeyo business to Neopharmed Gentili for up to $264 million. Closing of the transaction is expected by early October.The company said that it also remains on track to deliver net income and positive cash flows for the full year 2025.BCRX stock is up by about 12% this year and over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-announces-purchase-of-blade-urban-air-mobility-business/chrXN6wRdTY">Joby Aviation Stock Flies 15% After Company Announces Purchase Of Blade’s Urban Air Mobility Business: Retail’s Not Entirely Convinced</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level

CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 

Equity

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts 

ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes. 

Select Medical Expands Presence in Tennessee With Ballad Health Deal

SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses. 

BioCryst Pharmaceuticals, Inc. (BCRX) on Friday said that it has entered into a definitive agreement to sell its European Orladeyo business to Italian pharmaceutical company Neopharmed Gentili for up to $264 million.BCRX shares were up by over 4% in the pre-market session, following the news.As per the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-sale-european-orladeyor-berotralstat-business">agreement</a>, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo. Biocryst is also eligible to receive up to $14 million in future milestone payments.Orladeyo, also known as berotralstat, is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. Hereditary angioedema (HAE) is a rare genetic disorder causing recurring episodes of severe swelling in various body parts, including the limbs, face, intestinal tract, and airway.<a href="https://stocktwits.com/symbol/BCRX">BioCryst</a> plans to use the proceeds from the transaction to retire all remaining term debt of $249 million from Pharmakon, which will eliminate approximately $70 million of future interest payments.The biotech company expects the transaction to result in at least $50 million in expected annual operating expense savings for BioCryst. It also expects to end 2027 with approximately $700 million in cash and no term debt, marking an increase of $400 million from its previous 2027 net cash guidance.In the first quarter (Q1) of 2025, BioCryst reported Orladeyo net revenue of $134.2 million, marking a growth of 51% year-on-year. Oraledyo revenue, in fact, accounted for about 92% of the company’s overall revenue in the period.However, sales from the U.S. contributed 89.5% of global Orladeyo net revenues in the first quarter, implying the European business accounted for only a small portion.On Stocktwits, retail sentiment around BCRX stayed unchanged within ‘bearish’ territory over the past 24 hours, accompanied by ‘low’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1250/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_27_at_7_45_04_AM_png_68794667d1.webp" alt="BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits" width="1250" height="134"><figcaption>BCRX's Sentiment Meter and Message Volume as of 7:45 a.m. ET on June 27, 2025 | Source: Stocktwits</figcaption></figure>However, a Stocktwits user expressed surprise at the deal and opined that the additional cash makes it easier for the company to find a buyer if that is what it intends to do.<stembedurl>https://stocktwits.com/justfkntrade/message/619211689</stembedurl>Another opined that the deal makes the company an ‘irresistible candy’ with no debt.<stembedurl>https://stocktwits.com/gdesivir/message/619209736</stembedurl>Biocryst had also said in May that it expects to be profitable for the full year 2025, a year ahead of schedule.BCRX stock is up by 28% this year and by about 58% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-slams-eu-as-closed-for-business-after-200-m-fine-warning-of-daily-penalties/chmguP6RRIt">Meta Slams EU As ‘Closed For Business’ After $200M Fine, Warning of Daily Penalties</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish

As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up to $14 million in future milestone payments.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$7.78
Prev Close	$7.96
Open	$7.90
Dividend Yield	0.00%
50-Day Moving Average	$8.33
Beta	1.05
Avg. Volume	2.94M
PE Ratio	-44.30

52-Week High	$11.31
52-Week Low	$6.02
Market Capitalization	$1.62B
EPS (Annual)	-$0.43
Price to Book	-3.83
Revenue Per Employee	$777,089.66
Enterprise Value/EBITDA	N/A

BCRX
Biocryst Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCRX News

BCRX Biocryst Pharmaceuticals Inc.